<DOC>
	<DOCNO>NCT01263002</DOCNO>
	<brief_summary>An open study evaluate Efficacy , Safety Clevudine monotherapy Adefovir Clevudine combination Proportion Roadmap Concept patient chronic hepatitis B Associated Hepatocellular Carcinoma</brief_summary>
	<brief_title>A Study With Clevudine Monotherapy Adefovir Clevudine Combination Proportion Roadmap Concept Patients With HBV Associated-HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<criteria>Inclusion Criteria 1 . Patient chronic HBV DNA and/or symptom liver cirrhosis 2 . Patient Hepatocellular carcinoma evidence sonography , CT scan , MRI scan ) 3 . Patient 18 year old . 4 . Patient document HBsAg positive &gt; 6 month . Laboratory report prove HBsAg positive HBeAg positive least six month IgM antiHBc negative , IgG antiHBc positive screen 5 . Patient HBV DNA positive DNA level â‰¥ 2,000 IU/mL within 30 day baseline . 6 . Patient ALT AST level &gt; =40 IU/L 7 . Cell carcinoma/hepatocellular carcinoma patient anticipate live least 1 year . 8 . Patient fully active , able carry predisease performance without restriction restrict physically strenuous activity ambulatory able carry work light sedentary nature , e.g. , light house work , office work . 9 . Patient classify NYHA functional classification grade 12 . ( NYHA ; New York Heart Association ) 10 . Patient able give write informed consent prior study start comply study requirement . Exclusion Criteria 1 . Patient currently receive antiviral therapy . 2 . Patients previously treat interferon , peginterferon immunomodulatory within previous 6 month . 3 . Patients previously treat clevudine , lamivudine , adefovir , entecavir , telbivudine , tenofovir investigational nucleoside HBV infection . 4 . Patient coinfected HCV , HDV HIV . 5 . Patient metastatic malignancy . 6 . Patient previous liver transplantation 7 . Patient pregnant breastfeeding . 8 . Patient clinically relevant history abuse alcohol drug . 9 . Patient use oriental medicine within previous 2 week . 10 . Patient significant immunocompromised , gastrointestinal , renal , hematological , psychiatric , bronchopulmonary , biliary disease exclude asymptomatic GB stone , neurological , cardiac , oncologic ( except HCC ) allergic disease medical illness investigator 's opinion might interfere therapy . 11 . Patient creatinine clearance le 60mL/min estimate follow formula : ( 140age year ) ( body weight [ kg ] ) / ( 72 ) ( serum creatinine [ mg/dL ] ) [ Note : multiply estimate 0.85 woman ]</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>